EGFR and lung adenocarcinoma: Furthermore, si-circPRKCI can enhance the inhibitory effect of epidermal growth factor receptor (EGFR)–tyrosine kinase inhibitors in HCC827 cells, which may enhance the therapeutic effect of these inhibitors in lung adenocarcinoma with EGFR mutations (7).